Skip to main content
OpenTrials
Completed

NCT Number: NCT04587674

Identification of Outcome Predictors and Stratification of Responder Profiles Implanted With Spinal Cord Stimulation. An AI-based-pathway & Algorithmic Approach to Treat Failed Back Surgery Syndrome Patients

Failed Back Surgery Syndrome is commonly defined as new, recurrent, or persistent pain in the back and/or leg(s) of at least 6-month duration following spinal surgery. The literature estimates that 10-50% of patients undergoing spinal surgery are likely to develop such pain, representing a substantial financial burden. Among them, 5-10% would suffer from severe pain, which are intense, neuropathic and generally refractory to conventional therapeutic strategies considerably affect patients' functional capacity as well as their psychological and social well-being.

Spinal Cord Stimulation (SCS) is a well-established therapy to alleviate severe intractable neuropathic pain such as FBSS. SCS is a safe and reversible treatment option, which leads to improvement in pain relief and quality of life for patients with FBSS. Despite encouraging results in a chronic painful patient population that is refractory to conventional therapies, the literature estimates that only 58% [53% - 64%] of patients implanted with SCS devices achieved adequate pain relief.

FBSS population characterization and stratification and predictive modeling of SCS outcome are thus crucial to delineate future treatment options and to deliver neuromodulation therapy to the right patient.

The investigators designed a clinical prospective project based on SCS outcome optimization and SCS candidates' stratification: PREDIBACK 2.

This study would be a following part of a continuous project (PREDIBACK) that aims to better understand and stratify the therapies (drugs, surgery, psychological therapy or SCS) proposed to FBSS patients. The goal of PREDIBACK 1 was to develop a decision tool that simplifies the therapeutic decision process.

PREDIBACK 2 will focus on the neuromodulation pathway. Easing and helping patient orientation should improve referral yielding to specialists and accelerate patient flow through care pathway. Hence, facilitating access to adequate therapies for FBSS patients who usually have a longstanding history of pain.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Pain, Intractable Neurologic Manifestations Pain Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Caen Univerisity Hospital, Caen, France

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Selection Criteria:

  • Subject is ≥ 18 years and ≤ 80 years.
  • Subject has FBSS and does not require further surgery. For the purpose of this study, FBSS is defined as persistent or recurrent low back and leg pain of at least 6-month duration following at least one decompression and/or fusion procedure.
  • Subject has persistent low back and leg pain despite other treatment modalities (pharmacological, surgical, physical, or psychological therapies) that have been tried and did not prove satisfactory or are unsuitable or contraindicated for the subject.
  • VAS global pain is ≥ 50 mm.
  • Subject meets the criteria for spinal cord stimulation test according to HAS guidelines (multidisciplinary consultation, psychological assessment...).
  • Absence of active psychosis or history of serious psychotic illness requiring hospitalization.
  • Subject understands and accepts the constraints of the study.
  • Patient covered by French national health insurance.
  • Patient who has given written consent to the study after having received clear information.

Non-inclusion Criteria:

  • Subject is or has been treated with SCS, subcutaneous or peripheral nerve stimulation, an intrathecal drug delivery system, requires back surgery at the localization related to his/her original back pain complaint or experimental therapies.
  • Subject low back pain is coming from a non-FBSS etiology (i.e. cancerous pain, infectious disease, etc.).
  • Cause of low back pain accessible to etiological "mechanical" surgical treatment (discogenic low back pain, vertebral instability, spinal deformity, etc.).
  • Subject had most recent back surgery less than 6 months ago.
  • Simultaneous participation to any interventional study during the study
  • Subject requiring closer protection, i.e. minors, pregnant women, nursing mothers, subjects deprived of their freedom by a court or administrative decision, subjects admitted to a health or social welfare establishment, major subjects under legal protection, and finally patient in an emergency setting.
  • MRI contraindications if MRI is not available within a time frame of 2 years from the last spinal surgery. Absolute contraindications are: Cardiac implantable electronic device, metallic intraocular foreign bodies, cochlear implants, drug infusion pumps, catheters with metallic components, cerebral artery aneurysm clips, magnetic dental implants, tissue expander, artificial limb, hearing aid, piercing

Treatment and study plan

Spinal Cord Stimulation

Device

Lead(s) and Implant Pulse Generator

Primary outcomes

  1. Composite SCS efficacy score

    Time frame: 6 months

    Rate of SCS responders is defined as having at least three of these criteria:

    • Having at least a 30% decrease in Oswestry Disability Index (ODI) percentage. 10 items ranging from 0 to 5 where 0 indicates high ability and 5 indicate the inability.
    • Having at least a 50% decrease in the Visual Analogic Scale (VAS) (0 = no back pain, 10=worst imaginable pain)
    • Having at least a 0.2 points increase in the EuroQol-5 Dimensions (EQ-5D) questionnaire score. The maximum score of 1 indicates the best possible quality of life.
    • Having a decrease of 1.4 points in the Hospital Anxiety-Depression Scale (HADS) score. The total score ranges from 0 to 24 for each category.
    • 30% decrease pain surface (cm²): pain will assess painful area in terms of intensity, surface and pain typology.
    • Having a Patient Global Impression of Change (PGIC) score of at least 6. PGIC is a 7-point scale.
    • Drug intake will be measured using the Medication Quantification Scale (MQS) with a reduction of 3.4 points.

Secondary outcomes

  1. Pain intensity

    Time frame: 6 months

    Pain intensity will be assessed using the Visual Analogic Scale (VAS score : 0 "no pain" to 10 "worst pain")

  2. Pain surface

    Time frame: 6 months

    Pain mapping criteria will be compared. Pain mapping criteria include: Global Pain Surface (cm²), Pain intensities associated with the surface measurements, Mechanical/neuropathic components of pain surfaces.

  3. Functional capacity

    Time frame: 6 months

    Functional capacity will be assessed using the Oswestry Disability Index (ODI, 0 "no disability" to 100% "complete disability")

  4. Impact of Quality of life

    Time frame: 6 months

    Quality of life will be assessed using the EuroQol Five Dimensions index (EQ5D, 0 "dead" to 1 "perfect health")

  5. Psychological distress

    Time frame: 6 months

    Psychological distress will be assessed using the Hospital Anxiety and Depression Scale (HADS, For each subscale the total score is at most 21. A score of ≥11 is considered a clinically significant disorder)

  6. Social insecurity

    Time frame: 6 months

    Social insecurity will be assessed using the EPICES questionnaire [0 = low risk of insecurity to 100 = high risk of insecurity]

  7. Psychological resilience

    Time frame: 6 months

    Psychological resilience will be assessed using the CD-RISC-10 (10-item Connor-Davidson Resilience Scale) questionnaire. [0 = low resilience to 40 = high resilience]

  8. Effects of the technical parameters and Spinal Cord Stimulation devices on paresthesia

    Time frame: 6 months

    % of Type of lead (Spinal Cord Stimulation Monocolumn vs Multicolumn Lead)

  9. Effects of the technical parameters and Spinal Cord Stimulation devices on paresthesia

    Time frame: 6 months

    Stimulation intensity (mA, milliAmper)

  10. Effects of the technical parameters and Spinal Cord Stimulation devices on paresthesia

    Time frame: 6 months

    Stimulation pulse width (µs, microsecond)

  11. Effects of the technical parameters and Spinal Cord Stimulation devices on paresthesia

    Time frame: 6 months

    Stimulation frequency (Hz, Hertz)

  12. Effects of the technical parameters and Spinal Cord Stimulation devices on paresthesia

    Time frame: 6 months

    % of Stimulation Waveform (Low Dose, High Dose, Both), Electrical parameters

  13. Spinal Cord Stimulation efficacy using objective measurement tools

    Time frame: 6 months

    Intellis/SnapshotTM platform to the ActiGraph GT9X.

    -Duration of standing position given by both Intellis and GT9X,

  14. Spinal Cord Stimulation efficacy using objective measurement tools

    Time frame: 6 months

    Intellis/SnapshotTM platform to the ActiGraph GT9X.

    -Duration of sitting position given by both Intellis and GT9X,

  15. Spinal Cord Stimulation efficacy using objective measurement tools

    Time frame: 6 months

    Intellis/SnapshotTM platform to the ActiGraph GT9X.

    -Duration of lying position given by both Intellis and GT9X,

  16. Spinal Cord Stimulation efficacy using objective measurement tools

    Time frame: 6 months

    Intellis/SnapshotTM platform to the ActiGraph GT9X.

    -Duration of mobile position (activity) given by both Intellis and GT9X,

  17. Spinal Cord Stimulation efficacy using objective measurement tools

    Time frame: 6 months

    Intellis/SnapshotTM platform to the ActiGraph GT9X.

    -Number of steps given by GT9X,

  18. Spinal Cord Stimulation efficacy using objective measurement tools

    Time frame: 6 months

    Intellis/SnapshotTM platform to the ActiGraph GT9X.

    -Sleep duration given by GT9X,

  19. Spinal Cord Stimulation efficacy using objective measurement tools

    Time frame: 6 months

    Intellis/SnapshotTM platform to the ActiGraph GT9X.

    -Sleep efficacy given by GT9X,

  20. Spinal Cord Stimulation efficacy using objective measurement tools

    Time frame: 6 months

    Intellis/SnapshotTM platform to the ActiGraph GT9X.

    -Sleep onset latency given by GT9X,

Sponsors and collaborators

Lead sponsor

Poitiers University Hospital

Other

Registry information

Acronym: PREDIBACK 2

Important dates

Study start
2021
Primary completion
2024
Study completion
2025
First posted
Oct 14, 2020
Registry last updated
May 30, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.